Saturday, July 27, 2024

Ferrari and SK On Partner to Drive Innovations in Battery Cell Technology

- Advertisement -
- Advertisement -

SK On has announced a partnership with Ferrari to advance innovations in battery cell technology. The memorandum of understanding (MoU) signed between the two companies aims to explore new possibilities and potential solutions to enhance cell technology, though specific details about the technologies or formats involved were not disclosed.

SK On has been Ferrari’s exclusive battery partner since 2019, supplying battery cells for Ferrari’s plug-in hybrid electric vehicles (PHEVs). These batteries have been used in models such as the SF90 Stradale supercar, SF90 Spider convertible, 296 GTB, and 296 GTS. The MoU signifies a deeper collaboration between the two companies to drive forward advancements in battery technology.

“We are excited to join Ferrari’s electrification journey,” said Lee Seok-hee, CEO of SK On. “Combining expertise and technologies from the two companies, we expect to provide customers with new experiences and values.”

Ferrari CEO Benedetto Vigna expressed similar enthusiasm for the partnership, stating, “When companies and suppliers come together, collaboration powers common progress. We are working together with SK On to explore new frontiers and fuel the energy of shared ideas.”

Ferrari’s strategic plan, unveiled in 2022, aims to electrify 60% of its models by 2026, with a focus on plug-in hybrids and fully electric vehicles. By 2030, the company aims to have 80% of its lineup electrified, with 40% being purely electric and 40% partially electric. Vigna confirmed in a November 2023 interview that the development of Ferrari’s first electric model is on track, with plans for it to hit the road in the fourth quarter of 2025. The electric Ferrari will be manufactured at the company’s EV factory in Maranello, which is currently under construction to support the production of hybrid and electric sports cars.

- Advertisement -

Subscribe
Latest news
- Advertisement -
Related news
- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here